The latest phase 2 readout for Q32 Bio's alopecia hopeful received a warm reception from investors,...
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
The latest phase 2 readout for Q32 Bio's alopecia hopeful received a warm reception from investors, backing up the biotech's claim that the drug could offer...
Author: Fierce Biotech
Read Original Article